April 16, 2015 | Sun Pharmaceutical Industries and the Technion Israel Institute of Technology announced that they have entered into a worldwide research and licence agreement. The agreement is aimed at the development of a joint project, based on findings made by Nobel Prize laureate Aaron Ciechanover, that could potentially lead to the development of anti-cancer drugs.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments